Linkedin
RLS logo_header
Linkedin

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology

“Today’s alliance with Secarna highlights once more the versatility of our technology suite and the range of opportunities we can tackle with partners that are complementary to our R&D focus in oncology,” commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “AOCs represent a very attractive additional pocket in our industry where our expertise and antibody conjugation technology can enable unique therapeutic modalities. We are thrilled to partner with Secarna, a renowned expert in the field of developing oligonucleotide-based therapies.”

Read the full story on "VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology"

Share:

More News

Interim Safety Data in Ph 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients Reported

“Our goal is not simply to complete a Phase 1 trial; it is to deliver a re-sensitization solution that changes the post-progression treatment paradigm and positions Kairos as the essential complement to the EGFR-targeted therapy market with this clean safety profile now confirmed across 13 patients,” said Dr. John Yu,

Ph 3 Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as 1L PD-L1-Neg Non-Squamous NSCLC Met Primary Endpoint 

Dr. Michael GE, CEO of Kelun-Biotech, stated: “We are delighted to see that sac-TMT combined with pembrolizumab has achieved exciting positive results compared with immunotherapy plus chemotherapy in the first-line treatment of patients with PD-L1-negative NSCLC. This ADC plus immunotherapy regimen has previously demonstrated superior efficacy over immunotherapy monotherapy in

Fast Track Designation for Pelareorep in 2L+ Anal Cancer

“This Fast Track designation represents another important regulatory milestone for Oncolytics and reflects the significant progress we have made over the past twelve months in advancing pelareorep toward potential registration,” said Jared Kelly, Chief Executive Officer of Oncolytics. “During that time, we have received Fast Track designation in both metastatic

KEYTRUDA Monotherapy Significantly Improved PFS vs chemo in Certain Patients With Advanced or Recurrent MMR-deficient Endometrial Cancer 

“These findings build upon the well-established role of KEYTRUDA in endometrial cancer, one of the few cancers with rising incidence rates,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. “We are committed to helping women facing this disease by advancing potential treatment options. We thank the